siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells
<p>Abstract</p> <p>Background</p> <p>Doxorubicin is an effective breast cancer drug but is hampered by a severe, dose-dependent toxicity. Concomitant administration of doxorubicin and another cancer drug may be able to sensitize tumor cells to the cytotoxicity of doxoru...
Main Authors: | Yang Mingfeng, Zhen Zhuan, Feng Jianguo, Zer Cindy, Liu Anding, Dong Xuejun, Zhong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-05-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/9/133 |
Similar Items
-
Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential
by: Batchu Ramesh B, et al.
Published: (2005-07-01) -
Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin
by: Zou S, et al.
Published: (2012-07-01) -
Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer
by: Zhuang J, et al.
Published: (2021-03-01) -
siRNA therapy for cancer
by: Edinger, Daniel
Published: (2013) -
Mirror siRNAs loading for dual delivery of doxorubicin and autophagy regulation siRNA for multidrug reversing chemotherapy
by: Bo Yang, et al.
Published: (2020-10-01)